Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term tu [Therapeutic. Found 6 abstracts

Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer N. Rectal cancer clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2005 Jul;3(4):492-508.
Langer CJ. Role of zoledronic acid in the setting of bone metastases from non-small-cell lung cancer. Clinical lung cancer. 2005 Jan;6(5):314-6, 2005 Mar.
Rogers B. Looking at lymphoma and leukemia. Nursing. 2005 Jul;35(7):56-63; quiz 63-4.
Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
Langer C, Damsker J, Ridge A. Reirradiation: exploring new territory in the therapy of recurrent head and neck cancer. Clinical Advances in Hematology & Oncology. 2003 Jul;1(7):424-9, 440.
Langer CJ, Curran WJ, Keller SM, Catalano RB, Litwin S, Blankstein KB, Haas N, Campli SN, Comis RL. Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation.[see comment]. Cancer Journal From Scientific American. 1996 Mar;2(2):99-105.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term tu [Therapeutic

tu [Therapeutic Use] Antineoplastic Combined Chemotherapy Protocols 0 (Antineoplastic Combined Chemotherapy Protocols) dt [Drug Therapy] Lung Neoplasms tu [Therapeutic Use] rt [Radiotherapy] Adjuvant Radiotherapy Non-Small-Cell Lung Carcinoma Squamous Cell Carcinoma th [Therapy] sc [Secondary] Camptothecin aa [Analogs & Derivatives] Survival Analysis Female pa [Pathology] Combined Modality Therapy Neoplasm Staging di [Diagnosis] 7689-03-4 (Camptothecin) 0 (Imidazoles) Enzyme Inhibitors 118072-93-8 (zoledronic acid) Liver Neoplasms ai [Antagonists & Inhibitors] Taxoids Lymphoma 951-77-9 (Deoxycytidine) 0 (Organoplatinum Compounds) 58-05-9 (Leucovorin) 53643-48-4 (Vindesine) Non-US Gov't Support Time Factors Small Cell Carcinoma et [Etiology] 0 (Taxoids) Secondary Hypertrophic Osteoarthropathy 0 (Folfox protocol) 0 (Diphosphonates) 51-21-8 (Fluorouracil) Imidazoles Treatment Outcome mo [Mortality] Social Support Diphosphonates nu [Nursing] su [Surgery] 33419-42-0 (Etoposide) Rectal Neoplasms Middle Aged Leukemia Brain Neoplasms Head and Neck Neoplasms EC 1-17-4 (Ribonucleotide Reductases) Male Radiotherapy Organoplatinum Compounds Comparative Study Drug Therapy 103882-84-4 (gemcitabine) co [Complications] Antineoplastic Antimetabolites Human ad [Administration & Dosage] Fluorouracil Phytogenic Antineoplastic Agents Patient Education North America Antineoplastic Agents Ribonucleotide Reductases Phytogenic) 0 (Antineoplastic Agents Pulmonary Surgical Procedures mt [Methods] Bone Neoplasms 0 (Radiation-Sensitizing Agents) Disease Progression Antineoplastic) 0 (Antimetabolites Cisplatin Lymphatic Metastasis Leucovorin 0 (Antineoplastic Agents) Local Neoplasm Recurrence Clinical Trials Etoposide Type I DNA Topoisomerases 15663-27-1 (Cisplatin) Survival Rate Deoxycytidine st [Standards] 100286-90-6 (irinotecan) Vindesine Radiation-Sensitizing Agents 0 (Enzyme Inhibitors) Medical Oncology 0 (IFL protocol) Type I) EC 5-99-1-2 (DNA Topoisomerases
Last updated on Thursday, April 02, 2020